MASI vs GMED

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 10, 2026

MASI

52.7
AI Score
VS
MASI Wins

GMED

39.5
AI Score

Investment Advisor Scores

MASI

53score
Recommendation
HOLD

GMED

40score
Recommendation
AVOID NEW MONEY

AI Analyst Insights

Detailed Metrics Comparison

Metric MASI GMED Winner
Forward P/E 40.8163 13.2802 GMED
PEG Ratio 4.8334 1.7253 GMED
Revenue Growth 8.5% -0.7% MASI
Earnings Growth 214.4% 18.2% MASI
Tradestie Score 52.7/100 39.5/100 MASI
Profit Margin 4.9% 17.8% GMED
Beta 1.00 1.00 Tie
AI Recommendation HOLD AVOID NEW MONEY MASI

Relative Price Performance (Last 90 Days)

MASI 1M: +0.9% · 3M: +2.5% GMED 1M: -1.3% · 3M: -12.2%

Current Technical Phase

MASI

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (0.5% over 20 days), RSI 75

RSI (14): 74.8 · Price: $179.95

GMED

Distribution
Trim / tighten stop

Price near a flattening SMA50 (slope -2.5%) with fading momentum, RSI 46

RSI (14): 45.6 · Price: $75.23

Fundamentals Snapshot

Metric MASI GMED
Market Cap — —
Forward P/E 27.3 14.1
Trailing P/E 44.2 18.8
Revenue (TTM) — —
Revenue Growth 0.1% 0.0%
Gross Margin 0.6% 0.7%
Operating Margin 0.2% 0.2%
EPS 4.07 4.06
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, MASI is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.